Research funding

Development of new potential drugs with antimicrobial activity

2020-2022 - Czech Science Foundation (GA ČR): 20-19638Y (Design and investigation of novel antimicrobial agents active against drug-resistant and biofilm-forming gram-positive bacteria; principle investigator Assoc. Prof. M. Krátký)
2017-2019 - Czech Science Foundation (GA ČR): 17-27514Y (Peptide Drug Delivery Systems Targeting Macrophages for Antimycobacterial Active Compounds; principle investigator Dr. M. Krátký)
2012-2015 - Ministry of Health IGA NT 13346: Design and enzyme targeting of antibacterial active compounds against multidrug resistant strains. (principle investigator Vinšová J.)
2012-2015 - FAFIS - European project (CZ.1.07/2.2.00/28.0194)
2012-2015 – TEAB – European project (CZ. 1.07/2.3.00/20.0235)
2010-2011 - Bilateral project “Kontakt” Czech Republic - Slovenia: Development of novel antituberculosis agents and prodrugs effective against multidrug resistant tuberculosis. (principle investigator Vinšová J.)
2009-2011 - Ministry of Health IGA NS 10367-3: Evaluation and development of new perspective antimycobacterial drugs and prodrugs active against multidrug resistant strains. (principle investigator Vinšová J.)

2010-2012 - GAUK 27610: Synthesis of novel salicylanilide prodrugs with potential antibacterial and antifungal activity. (investigators: Krátký M., Rychtarčíková Z.)
2012 - FRVŠ 665/G6 Synthesis of antimicrobial active anilide/salicylanilide derivatives (investigators Kozic J., Krátký M.)

Ongoing

since 2022 - Member of the project National Institute of virology and bacteriology - NIVB (Programme EXCELES, ID Project No. LX22NPO5103) funded by the European Union - Next Generation EU.
since 2022 - Charles University project 392822: Structure-activity relationships in the group of antimycobacterial pyrimidine derivatives
2021-2024 Czech Health Research Council project NU21-05-00446 From hit-to-lead candidate – development of novel agents to combat tuberculosis
2018-2023 EU-funded project Efficiency and safety improvement of current drugs and nutraceuticals: advanced methods – new challenge (EFSA-CDN). Reg. No. CZ.02.1.01/0.0/0.0/16_019/0000841

2015-2017: Project GAUK (361215) - Synthesis of potential antituberculotics and their in vitro and in vivo evaluation (Syntéza potenciálních antituberkulotik a jejich hodnocení in vitro a in vivo)
2014-2016: Czech Science Foundation 14-08423S - Structure-activity-toxicity relationships studies in the group of small-molecule compounds with antimycobacterial activity
2012-2015: EU project "Pre-Seed" Reg. No. CZ.1.05/3.1.00/13.0284
2014-2015: EU project "Pre-Seed II" Reg. No. CZ.1.05/3.1.00/14.0299
2010-2012: Charles University project 55610/2010 "Synthesis and properties of selenium analogues of sulphur antituberculotics"
2010 - Ministry of education project FRVS 534/2010/F6/a
2005 - 2011: Ministry of education project 1M6138896301 "Centre for new antivirals and antineoplastics"
2005 - 2011: Ministry of education project MSM 0021620822 "Research of new drugs"

since 2022: Charles University project 361422: Synthesis and study of cardioprotective activity of topoisomerase II beta inhibitors
2019-2023 EU-funded project Pre-application research into innovative medicines and medical technologies (InoMed), reg. no. CZ.02.1.01/0.0/0.0/18_069/0010046
2021-2023: Czech Science Foundation 21-16195S - Chemical biology approach to study anthracycline cardiotoxicity and pharmacological cardioprotection with focus on topoisomerase II beta

Charles University in Prague: "Centre for research of toxic and protective effects of drugs on cardiovascular system" (2012-2017)
2018-2020: Czech Science Foundation 18-08169S - Study of individual topoisomerase ii isoforms in anticancer and cardiotoxic effects of anthracyclines and their modulations by bisdioxopiperazines (2018 - 2020)
Czech Science Foundation (GA ČR): 13-15008S - New potential cardioprotective agents: study of structure-activity relationships in various types of myocardial injury (2013 - 2017)
2009-2012: Czech Science Foundation (Grant 305/09/0416) "Myocardial damage induced by anticancer drugs and ischemia-reperfusion : new possibilities of pharmacologicla cardioprotection"